Deep Vein Thrombosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Deep Vein Thrombosis stocks.

Deep Vein Thrombosis Stocks Recent News

Date Stock Title
Nov 20 SNY CDC warns of an imminent spike in COVID, flu cases
Nov 20 SNY Here’s What Drove Sanofi’s (SNY) Earnings
Nov 20 SNY Sanofi: Information concerning the total number of voting rights and shares - October 2024
Nov 18 SNY FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
Nov 18 NARI Inside a $400 billion bet on the brain-computer interface revolution
Nov 15 SNY How analysts are reacting to RFK Jr. as Trump's HHS pick
Nov 15 SNY FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
Nov 15 SNY Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.
Nov 15 SNY Stocks to Watch Friday: Applied Materials, Alibaba, Domino's, Novo Nordisk
Nov 15 SNY Trump’s RFK Jr. Pick Weighs on Vaccine Makers
Nov 15 SNY Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S.
Nov 15 SNY European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department
Nov 15 SNY EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma
Nov 15 SNY Drugmaker stocks slide as Trump picks vaccine sceptic RFK Jr for US health job
Nov 15 SNY Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Nov 15 SNY Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Nov 15 SNY Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
Nov 14 SNY Vaccine makers close lower amid reports RFK Jr may head HHS (update)
Deep Vein Thrombosis

Deep vein thrombosis (DVT), is the formation of a blood clot in a deep vein, most commonly the legs. Symptoms may include pain, swelling, redness, or warmth of the affected area. About half of cases have no symptoms. Complications may include pulmonary embolism, as a result of detachment of a clot which travels to the lungs, and post-thrombotic syndrome.Risk factors include recent surgery, cancer, trauma, lack of movement, obesity, smoking, hormonal birth control, pregnancy and the period following birth, antiphospholipid syndrome, and certain genetic conditions. Genetic factors include deficiencies of antithrombin, protein C, and protein S, and factor V Leiden mutation. The underlying mechanism typically involves some combination of decreased blood flow rate, increased tendency to clot, and injury to the blood vessel wall.Individuals suspected of having DVT may be assessed using a clinical prediction rule such as the Wells score. A D-dimer test may also be used to assist with excluding the diagnosis or to signal a need for further testing. Diagnosis is most commonly confirmed by ultrasound of the suspected veins. Together, DVT and pulmonary embolism are known as venous thromboembolism (VTE).Anticoagulation (blood thinners) is the standard treatment. Typical medications include low-molecular-weight heparin, warfarin, or a direct oral anticoagulant. Wearing graduated compression stockings may reduce the risk of post-thrombotic syndrome. Prevention may include early and frequent walking, calf exercises, aspirin, anticoagulants, graduated compression stockings, or intermittent pneumatic compression. The rate of DVTs increases from childhood to old age; in adulthood, about one in 1000 adults are affected per year. About 5% of people are affected by a VTE at some point in time.

Browse All Tags